Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1103-1110

  Kim, Dong Wook ^a   Ko, Seon Mi ^a   Jeon, Young Joo ^a   Noh, Young Woock ^b   Choi, Nag Jin ^c   Cho, Sung Dae ^a   Moon, Hong Seop ^d   Cho, Young Sik ^e   Shin, Jae Chen ^f,g   Park, Seon Min ^f   Seo, Kang Seok ^h   Choi, Ji Young ⁱ   Chae, Jung Il ^a   Shim, Jung Hyun ^d  

^a Chonbuk National University   (South Korea)

^b Chungnam National University   (South Korea)

^c School of Natural Resources and the Environment   (United States)

^d Mokpo National University   (South Korea)

^e Keimyung University   (South Korea)

^f Pohang Center of Evolution of Biomaterials   (South Korea)

^g Pohang University of Science and Technology (POSTECH)   (South Korea)

^h Sunchon National University   (South Korea)

ⁱ Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Apoptosis; Honokiol; Oral squamous cancer cell; Specificity protein 1

Indexed keywords

CASPASE 3; CYCLIN D1; HONOKIOL; PROTEIN MCL 1; PROTEIN P21; PROTEIN P27; SURVIVIN; TRANSCRIPTION FACTOR SP1;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IC 50; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SURVIVAL; TRANSACTIVATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; MOUTH NEOPLASMS; PLANTS; SP1 TRANSCRIPTION FACTOR;

EID: 84882438112     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2028     Document Type: Article

References (48)

1. Hamada T, Wakamatsu T, Miyahara M, et al: MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer 130: 1768-1776, 2012.
2. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316, 2009.
3. Newman DJ and Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75: 311-335, 2012.
4. Fried LE and Arbiser JL: Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 11: 1139-1148, 2009.
5. Fujita M, Itokawa H and Sashida Y: Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and honokiol in M. obovata and other allied plants. Yakugaku Zasshi 93: 429-434, 1973 (In Japanese).
6. Teng CM, Chen CC, Ko FN, et al: Two antiplatelet agents from Magnolia officinalis. Thromb Res 50: 757-765, 1988.
7. Liou KT, Lin SM, Huang SS, Chih CL and Tsai SK: Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med 69: 130-134, 2003.
8. Lo YC, Teng CM, Chen CF, Chen CC and Hong CY: Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 47: 549-553, 1994.
9. Kuribara H, Kishi E, Hattori N, Yuzurihara M and Maruyama Y: Application of the elevated plus-maze test in mice for evaluation of the content of honokiol in water extracts of magnolia. Phytother Res 13: 593-596, 1999.
10. Battle TE, Arbiser J and Frank DA: The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106: 690-697, 2005.
11. Shigemura K, Arbiser JL, Sun SY, et al: Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109: 1279-1289, 2007.
12. Garcia A, Zheng Y, Zhao C, et al: Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res 14: 4267-4274, 2008.
13. Deng J, Qian Y, Geng L, et al: Involvement of p38 mitogen activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int 28: 1458-1464, 2008.
14. Li Z, Liu Y, Zhao X, et al: Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol 140: 95-102, 2008.
15. Bai X, Cerimele F, Ushio-Fukai M, et al: Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278: 35501-35507, 2003.
16. Sheu ML, Chiang CK, Tsai KS, et al: Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic Biol Med 44: 2043-2050, 2008.
17. Lee J, Jung E, Park J, et al: Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 71: 338-343, 2005.
18. Tse AK, Wan CK, Shen XL, Yang M and Fong WF: Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochem Pharmacol 70: 1443-1457, 2005.
19. Li L and Davie JR: The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192: 275-283, 2010.
20. Hirano T, Gotoh M and Oka K: Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci 55: 1061-1069, 1994.
21. Yang SE, Hsieh MT, Tsai TH and Hsu SL: Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol 63: 1641-1651, 2002.
22. Abdelrahim M, Smith R III, Burghardt R and Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64: 6740-6749, 2004.
23. Ishibashi H, Nakagawa K, Onimaru M, et al: Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 60: 6531-6536, 2000.
24. Kong LM, Liao CG, Fei F, Guo X, Xing JL and Chen ZN: Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci 101: 1463-1470, 2010.
25. Chuang JY, Wu CH, Lai MD, Chang WC and Hung JJ: Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer 125: 2066-2076, 2009.
26. Choi ES, Shim JH, Jung JY, et al: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 102: 742-748, 2011.
27. Shim JH, Shin JA, Jung JY, et al: Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev 20: 102-111, 2011.
28. Davie JR, He S, Li L, et al: Nuclear organization and chromatin dynamics-Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul 48: 189-208, 2008.
29. Grinstein E, Jundt F, Weinert I, Wernet P and Royer HD: Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 21: 1485-1492, 2002.
30. Chen F, Zhang F, Rao J and Studzinski GP: Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. Anticancer Res 20: 661-667, 2000.
31. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA and Miller DM: Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613-1621, 1991.
32. Porter PL, Malone KE, Heagerty PJ, et al: Expression of cell cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997.
33. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
34. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
35. Murray AW: Recycling the cell cycle: cyclins revisited. Cell 116: 221-234, 2004.
36. Albanese C, Johnson J, Watanabe G, et al: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589-23597, 1995.
37. Lee RJ, Albanese C, Stenger RJ, et al: pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 274: 7341-7350, 1999.
38. Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527, 1999.
39. Weinstein IB: Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem (Suppl) 25: 23-28, 1996.
40. Li F: Survivin study: what is the next wave? J Cell Physiol 197: 8-29, 2003.
41. Xu R, Zhang P, Huang J, Ge S, Lu J and Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356: 286-292, 2007.
42. Chun JY, Hu Y, Pinder E, Wu J, Li F and Gao AC: Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 6: 2572-2580, 2007.
43. Yoon JH, Werneburg NW, Higuchi H, et al: Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 62: 6500-6505, 2002.
44. Okaro AC, Deery AR, Hutchins RR and Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 54: 927-932, 2001.
45. Akgul C: Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66: 1326-1336, 2009.
46. Andersson Y, Juell S and Fodstad O: Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-pseudomonas exotoxin a immunotoxin. Int J Cancer 112: 475-483, 2004.
47. Chetoui N, Sylla K, Gagnon-Houde JV, et al: Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6: 42-52, 2008.
48. Wei SH, Dong K, Lin F, et al: Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol 62: 1055-1064, 2008.